Donskov F, Viggo Jensen N, Smidt-Hansen T. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. AO [Internet]. 2018 May 4 [cited 2026 Jun. 29];57(5):589-94. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/24718